JÚN-08-2005 15:31 FROM:SANOFI PATENT DEPT 61/200398722

TO: USPTO CENTRAL FAX CENTRAS

JUN 0 7 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of BAKONYI et al.

Examiner:

SAEED, Kamal A.

Art Unit:

1626

Application No.: 10/718,925

Filed:

November 21, 2003

Title:

PROCESS FOR RACEMIZATION

TERMINAL DISCLAIMER

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs.

SANOFI-SYNTHELABO, the owner of one-hundred percent (100%) interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 6,670,486. The owner hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and prior U.S. Patent No. 6,670,486 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of prior U.S. Patent No. 6,670,486 as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Owner furthermore does not disclaim any extension of the term of any patent granted on the instant application that may be obtained under the provisions of 35 U.S.C. §§ 154-156.

P.5/5

و الحدد

Please deduct the fee of \$110.00 required by 37 C.F.R. §1.20(d) from Deposit

Account No. 18-1982.

Respectfully submitted,

Kelly L. Bender, Reg. No., 52,610 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626

Aventis Docket No. IVD1103 US DIV